bruceantin

Bruceantin is a naturally occurring quassinoid isolated from plants of the genus Brucea, primarily Brucea sumatrana and Brucea javanica of the Simaroubaceae family. Chemically it is a polycyclic diterpene lactone with the molecular formula C₂₃H₂₈O₆, characterized by multiple hydroxyl groups and an acetylated side chain. The compound was first identified in the 1970s during investigations of the bitter principles responsible for the medicinal properties of Brucea species, which have been used in traditional Asian medicine for dysentery and fever.

Biological activity studies revealed that bruceantin possesses potent cytotoxic effects against a range of human cancer cell lines, including leukemic, colorectal, and breast cancer models. Its primary mechanism of action is inhibition of protein synthesis through binding to the ribosomal peptidyl‑transferase center, leading to cell‑cycle arrest and apoptosis. Preliminary antimalarial, antiviral, and immunomodulatory activities have also been reported in vitro.

Based on its antitumor potency, bruceantin entered clinical evaluation in the 1980s for refractory acute lymphoblastic leukemia and solid tumours. Although limited objective responses were observed, dose‑limiting toxicities such as severe nausea, vomiting, and neutropenia curtailed further development, and the drug was not pursued for market approval.

Current research focuses on synthesizing structural analogues to retain anticancer efficacy while reducing toxicity, and on elucidating additional pharmacological targets. Extraction of bruceantin from Brucea plant material typically employs organic solvent extraction followed by chromatographic purification.